Ivonescimab + Chemotherapy for NSCLC

This trial tests a new treatment called ivonescimab for individuals with advanced non-small cell lung cancer (NSCLC). The researchers aim to determine if ivonescimab, alone or with chemotherapy, can shrink tumors and improve survival. Participants should have NSCLC with specific genetic alterations and have previously tried targeted therapies, with or without chemotherapy, depending on the trial group. Those with prior lung cancer treatments and specific genetic changes in their cancer might be eligible. As a Phase 2 trial, this research focuses on measuring the treatment's effectiveness in an initial, smaller group of people.

The trial information does not specify if you need to stop taking your current medications. However, if you are on certain medications like corticosteroids or anticoagulants, you may need to adjust your dosage or ensure stability before joining. It's best to discuss your specific medications with the trial team.

Research shows that ivonescimab, when used alone, can cause side effects such as low white blood cell count, nausea, diarrhea, low red blood cell count, hair loss, and tiredness. These side effects are manageable and often resemble those of other cancer treatments.

When combined with chemotherapy, studies have found ivonescimab to be generally safe, with a safety profile similar to other treatments. Patients in these studies experienced side effects like low blood counts and tiredness, which are expected with chemotherapy.

Unlike the standard treatments for non-small cell lung cancer (NSCLC), which mainly include targeted therapies, chemotherapy, and immune checkpoint inhibitors, Ivonescimab is unique because it combines targeted therapy with immune modulation. Researchers are excited about Ivonescimab because it targets specific genomic alterations in cancer cells and also enhances the immune system's ability to attack the cancer. This dual action could potentially improve treatment outcomes for patients who have progressed after standard therapies. Additionally, Ivonescimab, when combined with chemotherapy agents like carboplatin and pemetrexed, might bolster the effectiveness of these traditional treatments, offering a new hope for patients with advanced NSCLC.

Research has shown that ivonescimab, one of the treatments in this trial, holds promise for treating advanced non-small cell lung cancer (NSCLC). Participants may receive ivonescimab alone or with chemotherapy drugs carboplatin and pemetrexed. Studies have found that ivonescimab can significantly slow cancer growth. When combined with carboplatin and pemetrexed, ivonescimab has helped patients live longer without their cancer worsening, even after previous treatments. Additionally, ivonescimab has a good safety profile, causing few severe side effects. These findings suggest that ivonescimab could be a valuable option for NSCLC patients seeking new treatments.¹³⁴⁶⁷